Results of an 18-month trial led by US pharmaceutical producer Eli Lilly have shown its new Alzheimer's drug can delay the progression of the disease by up to 35.1 percent.
of the low/medium tau group who received donanemab had no change at all in their CDR-SB rating after one year, compared to only 29 percent of those who received the placebo.
Unfortunately, no significant improvement was seen for the high tau group when compared with the placebo. Throughout the trial, if any patient had a high enough clearance of amyloid-beta plaques, they were unknowingly moved off the drug and onto the placebo – a move intended to save money and unnecessary treatment. This occurred inWhat's interesting is such significant clearance of amyloid-beta plaques could be associated with relatively mild clinical impact, once again highlighting how much we still have to learn.
It's important to note there are some big limitations to the study – almost all of the participants were White, and the age of participants was restricted to between 60 and 85.More data is needed before we can tease out exactly who donanemab will most benefit and whether the potential side effects will be worth it. As Rabinovici and La Joie explain in their editorial, it's likely that we'll have better drug options in the future.
But for now, any hope is meaningful for people hoping to delay Alzheimer's disease just a few more months or years.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Lilly drug slows Alzheimer's by 60% for mildly impaired patients in trialAn experimental Alzheimer's drug from Eli Lilly has shown to significantly slow the progression from the brain-wasting disease. Researchers said the treatment works best if Alzheimer's patients are treated as early as possible
Lire la suite »
Second Alzheimer's drug in pipeline can slow the disease by a few months but with safety riskNew research shows another experimental Alzheimer's drug can modestly slow patients' inevitable worsening.
Lire la suite »
Second Alzheimer's drug in pipeline can slow the disease by a few months but with safety riskAnother experimental Alzheimer's drug can modestly slow patients' inevitable worsening — by about four to seven months, researchers reported Monday.
Lire la suite »
Second Alzheimer's drug in pipeline can slow the disease by a few months but with safety riskNew research shows another experimental Alzheimer's drug can modestly slow patients' inevitable worsening.
Lire la suite »
Major Change Proposed in How Alzheimer’s Is DiagnosedInternational experts are proposing that Alzheimer’s disease should be diagnosed using biomarkers – traits of a person’s health obtained by taking blood, fluid, and tissue samples – rather than testing memory and observing symptoms.
Lire la suite »
Second Alzheimer’s drug in pipeline can slow the disease by a few months but with safety riskAnother experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening — by about four to seven months, researchers reported Monday.
Lire la suite »